Akebia Therapeutics ®, Inc.

About Akebia Therapeutics ®, Inc.

Akebia Therapeutics ®, Inc. is a pioneering biopharmaceutical company dedicated to the development of innovative therapies for patients with kidney disease and other serious conditions. Founded with a vision to transform the treatment landscape, Akebia focuses on addressing unmet medical needs through its cutting-edge research and development efforts.

The company’s flagship product, Vadadustat, is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anaemia associated with chronic kidney disease (CKD). This groundbreaking therapy aims to improve patient outcomes by providing a novel approach to managing anaemia without the need for injectable erythropoiesis-stimulating agents.

In addition to Vadadustat, Akebia is committed to expanding its pipeline with new candidates that target various aspects of kidney health and related disorders. The company collaborates with leading academic institutions and industry partners to enhance its research capabilities and accelerate the development of its therapeutic candidates.

Akebia Therapeutics operates with a strong emphasis on scientific excellence and innovation, striving to bring forth solutions that can significantly improve the quality of life for patients. The company’s team comprises experienced professionals who are passionate about advancing healthcare and making a meaningful impact in the lives of those affected by chronic diseases.

With its headquarters located in the UK, Akebia is strategically positioned to leverage global opportunities in the biopharmaceutical sector. The company is also focused on building a sustainable business model that aligns with its mission to deliver transformative therapies while ensuring long-term growth and success.

As part of its commitment to corporate responsibility, Akebia actively engages in initiatives that promote patient education and awareness about kidney health. The company believes in fostering a collaborative environment where stakeholders can work together to drive innovation and improve patient care.

In summary, Akebia Therapeutics ®, Inc. stands at the forefront of biopharmaceutical innovation, dedicated to developing therapies that address critical health challenges faced by patients worldwide.